Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles

Fertility and Sterility

Volumn 96, Issue 3, 2011, Pages 585-589

  Dovey, Serena ^a   McIntyre, Kerri ^b   Jacobson, Debbie ^c   Catov, Janet ^a   Wakim, Anthony ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Premier Women's Health Obstetrics and Gynecology   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Flexible GnRH antagonist protocol; GnRH antagonist; IVF; luteinizing hormone (LH); premature LH rise

Indexed keywords

CETRORELIX; GANIRELIX; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; PROGESTERONE;

ADULT; ARTICLE; CELL COUNT; CONTROLLED STUDY; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; HUMAN; MAJOR CLINICAL STUDY; OOCYTE; OVARIAN RESERVE; PREGNANCY OUTCOME; PREGNANCY RATE; PRIORITY JOURNAL;

ADULT; COHORT STUDIES; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; INCIDENCE; INFERTILITY, FEMALE; LUTEINIZING HORMONE; MALE; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 80052262395     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2011.06.042     Document Type: Article

References (16)

1. G. Borm, B. Mannaerts The European Orgalutran Study Group Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe, and convenient: results of a controlled, randomized, multicentre trial Hum Reprod 15 2000 1490 1498
2. E.M. Kolibianakis, K. Zikopoulos, J. Schiettecaatte, J. Smitz, H. Tournaye, and M. Camus Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF Hum Reprod 19 2004 2490 2496 (Pubitemid 39481272)
3. P. Humaidan, L. Bungum, M. Bungum, and C. Yding Andersen Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-recombinant FSH stimulation Human Reprod 17 2002 2016 2021
4. E.M. Kolibianakis, C. Albano, J. Kahn, M. Camus, H. Tournaye, and A.C. Van Steirteghem Exposure to high levels of luteinizing hormone and estradiol in the earl follicular phase of gonadotropin-releasing hormone antagonist cycles in associated with a reduced chance of pregnancy Fertil Steril 79 2003 873 880 (Pubitemid 36385006)
5. M. Ludwig, A. Katalinic, C. Banz, A.K. Schroder, M. Loning, and J.M. Weiss Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study Hum Reprod 17 2002 2842 2845 (Pubitemid 35350899)
6. M.H. Mochtar Dutch Ganirelix Study Group The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI Hum Reprod 19 2004 1713 1718 (Pubitemid 39144610)
7. E. Escudero, E. Bosch, J. Crespo, C. Simon, J. Remohi, and A. Pellicer Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients Fertil Steril 81 2004 562 566 (Pubitemid 38376111)
8. E. Kolibianakis, C. Borgain, C. Albano, K. Osmanagaoglu, J. Smitz, and A. Van Steirteghem Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up Fertil Steril 78 2002 1025 1029 (Pubitemid 35292504)
9. H. Al-Inany, M.A. Aboulghar, R.T. Mansour, and G.I. Serour Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol Reprod Biomed Online 10 2005 567 570 (Pubitemid 40645532)
10. Ganirelix Dose-Finding Study Group A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Purgenon) Hum Reprod 13 1998 3023 3031
11. T. Erb, W. Vitek, and A. Wakim Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program Fertil Steril 93 2010 374 378
12. H.A. Beydoun, L. Stadtmauer, M.A. Beydoun, H. Russel, Y. Zhao, and S. Oehninger Polycystic ovary syndrome, body mass index and outcomes of assisted reproductive technologies Reprod Biomed Online 18 2009 856 863
13. E.S.T. Nejad, T. Saedi, S. Saedi, B.H. Rashidi, Z.A. Nekoo, and N. Jahangiri Comparison of in vitro fertilization success in patients with polycystic ovary syndrome and tubal factor Gynecol Endocrinol 27 2011 117 120
14. S.K. Sunkara, V. Rittenberg, N. Raine-Fenning, S. Bhattacharya, J. Zamora, and A. Coomarasamy Association between the number of eggs and live birth in IVF treatment: an analysis of 400,135 treatment cycles Hum Reprod 26 2011 1768 1774
15. I.E. Messinis, D. Loutradis, E. Domali, C.P. Kotsovassilis, L. Papastergiopoulou, and A. Kallitsaris Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment Hum Reprod 20 2005 3192 3197 (Pubitemid 41662677)
16. M. Sonmezer, A.P. Cil, C. Atabekoglu, S. Ozakuvukeu, and B. Ozmen Does premature luteinization or early surge of LH impair cycle outcome? Report of two successful outcomes J Assist Reprod Genet 26 2009 159 163